SS Innovations International (NASDAQ: SSII) has brought robotic cardiac surgery to Sri Lanka for the first time, launching a program at Kings Hospital Colombo with its SSi Mantra 3.0 surgical robotic system. The inaugural procedure, a robotic-assisted left internal mammary artery (LIMA) takedown, was performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva.
The program's early activity has been robust: Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to a recent company video. This rapid adoption signals strong local demand for advanced surgical technology and could pave the way for broader use of robotic systems in Sri Lanka's healthcare system.
For SS Innovations, the launch represents another step in its global expansion. The company reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. Revenue for the quarter reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of its installed base. These figures suggest that the company is not only selling systems but also seeing surgeons increasingly rely on them for complex operations.
The next major corporate milestone is regulatory expansion. SS Innovations is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Success in these markets could significantly broaden the company's addressable market and accelerate adoption among hospitals in high-income countries. However, the regulatory process is subject to risks and uncertainties, as noted in the company's forward-looking statements.
The entry into Sri Lanka's cardiac surgery sector is important because it demonstrates the potential for robotic surgery to reach emerging markets, where access to advanced medical technology has traditionally been limited. For patients, robotic-assisted cardiac surgery can mean smaller incisions, reduced pain, and faster recovery compared to traditional open-heart procedures. For the healthcare industry, it highlights the growing competition among surgical robotics companies to establish a presence in new geographies.
As SS Innovations continues to expand, its progress will be closely watched by investors and medical professionals alike. The company's ability to secure regulatory approvals in the U.S. and Europe, while simultaneously growing its installed base in markets like Sri Lanka, will be key to its long-term success. For now, the launch at Kings Hospital Colombo stands as a tangible example of how robotic surgery is transforming cardiac care in South Asia.
For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website: https://IBN.ai/Disclaimer. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
